FDA Warning Letter & FTC Consent Order Atlas
Every regulatory action against hormone, peptide, and weight-loss marketers since 2015.
Searchable. Sourced. Structured for AI citation.
What you are looking at
The six entries below are illustrative examples adapted from the public FDA Warning Letter and FTC consent-order corpus. Specific recipient names and exact penalty amounts are anonymized until the full Atlas launches in Q3 2026 with direct links to each source document on fda.gov and ftc.gov. The summarized claims and enforcement themes are accurate; the company labels are placeholders.
Filters
Type
Sub-vertical
6 entries · Sample data, full corpus at launch
TRT clinic, VA (recipient anonymized)
Unapproved new drug claims for testosterone preparations marketed without FDA approval. Claims included 'reverses aging' and 'clinically proven to restore youthful testosterone levels.'
Peptide marketer (recipient anonymized)
Deceptive weight-loss claims for BPC-157 and TB-500 peptide injections. Settlement included a civil penalty and a prohibition on unsubstantiated efficacy claims.
GLP-1 / weight-loss clinic, TX (recipient anonymized)
Compounded semaglutide marketed with claims not supported by adequate substantiation. Site copy included patient testimonials with specific weight-loss outcomes.
DPC practice, FL (recipient anonymized)
Misleading claims about DPC membership benefits and cost savings. 'Save up to 80% on healthcare costs' claim lacked adequate substantiation.
IV therapy provider, NY (recipient anonymized)
IV vitamin infusion products marketed with disease treatment claims. 'Cures hangover in 30 minutes' and 'boosts immune system' claims cited.
TRT clinic, FL (recipient anonymized)
Testosterone pellet therapy marketed with claims of treating depression, fatigue, and cognitive decline without adequate clinical substantiation.
Run your site against this corpus
The free audit pattern-matches your marketing claims against every entry in this Atlas.
Run my free audit